全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Extractive Spectrophotometric Determination of Tenofovir Disoproxil Fumarate Using Acidic Triphenylmethane Dyes

DOI: 10.1155/2014/856760

Full-Text   Cite this paper   Add to My Lib

Abstract:

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor that has activity against the hepatitis B and HIV viruses. Three simple and sensitive extractive spectrophotometric methods have been described for the assay of tenofovir disoproxil fumarate either in pure form or in pharmaceutical formulations. The developed methods involve formation of colored chloroform extractable ion-pair complexes of the drugs with triphenylmethane dyes, namely, bromothymol blue (BTB), bromophenol blue (BPB), and bromocresol purple (BCP) in acidic medium. The extracted complexes showed absorbance maxima between 410 and 415?nm. Beer’s law is obeyed in the concentration ranges 1.5–25, 1.0–25, and 1.25–25?μg?mL?1 with BTB, BPB, and BCP, respectively. The effectc of concentration of dye, pH, and interference of excipients have been studied and optimized. The limits of detection and quantification have been determined. All three methods are validated as per the guidelines of ICH. The methods have been applied to the determination of drug in commercial tablets and results of analysis were validated statistically through recovery studies. 1. Introduction Tenofovir disoproxil fumarate (TDF) 9-[(R)-2-[[bis[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl] adenine fumarate is antiviral agent acts as nucleoside reverse transcriptase enzyme inhibitor [1]. It is a nucleoside analogue which is phosphorylated by host cell enzyme to give 5-triphosphate derivative. This moiety competes with the equivalent host cellular triphosphate for proviral DNA synthesis by viral reverse transcriptase which is viral RNA-dependent DNA polymerase. Incorporation of the 5-triphosphate moiety into the growing viral DNA chain results in chain termination. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults [2, 3]. The literature survey revealed that only few methods are available for the determination of tenofovir in dosage forms and include liquid chromatography with tandem mass spectrometry [4, 5]; HPLC with solid phase extraction [6]; reversed phase HPLC [7, 8]; HPLC with spectrophotometric detection [9]; HPTLC [10]; gradient ion-pair LC with fluorescent detector [11]; and HPLC-UV, HPLC-MS [12], and first-order UV derivative spectrophotometry [13, 14]. Visible spectrophotometry, because of its simplicity, cost-effectiveness, sensitivity, selectivity, fair accuracy, and precision, has remained competitive in pharmaceutical analysis. In a method described by Onah and Ajima, tenofovir [15] was quantified by complexation

References

[1]  M. D. Miller, N. Margot, B. Lu et al., “Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients,” Journal of Infectious Diseases, vol. 189, no. 5, pp. 837–846, 2004.
[2]  J. E. Gallant, E. Dejesus, J. R. Arribas et al., “Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV,” The New England Journal of Medicine, vol. 354, no. 3, pp. 251–260, 2006.
[3]  Viread (Tenofovir) a Product Monograph, Gilead Sciences, Foster City, Calif, USA, 2001.
[4]  T. King, L. Bushman, J. Kiser et al., “Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 843, no. 2, pp. 147–156, 2006.
[5]  T. Delahunty, L. Bushman, and C. V. Fletcher, “Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 830, no. 1, pp. 6–12, 2006.
[6]  N. L. Rezk, R. D. Crutchley, and A. D. M. Kashuba, “Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 822, no. 1-2, pp. 201–208, 2005.
[7]  S. Sentenac, C. Fernandez, A. Thuillier, P. Lechat, and G. Aymard, “Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 793, no. 2, pp. 317–324, 2003.
[8]  N. A. Raju and S. Begum, “Simultaneous RP-HPLC method for the estimation of Emtricitabine, Tenofovir and Efavirenz in tablet dosage forms,” Research Journal of Pharmacy and Technology, vol. 1, no. 4, pp. 522–525, 2008.
[9]  E. Rey, G. Pons, J. Treluyer, and V. Julien, “Determination of Tenofovir in Human plasma by HPLC with spectroflourimetric detection,” Journal of Chromatography B, vol. 785, no. 2, pp. 377–381, 2003.
[10]  M. Joshi, A. P. Nikalje, M. Shahed, and M. Dehghan, “HPTLC method for the simultaneous estimation of emtricitabine and tenofovir in tablet dosage form,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 1, pp. 95–97, 2009.
[11]  R. W. Sparidans, K. M. L. Crommentuyn, J. H. M. Schellens, and J. H. Beijnen, “Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 791, no. 1-2, pp. 227–233, 2003.
[12]  M. E. Barkil, M.-C. Gagnieu, and J. Guitton, “Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 854, no. 1-2, pp. 192–197, 2007.
[13]  A. Shirkhedkar Atul, H. Bhirud Charushila, and J. Surana Sanjay, “Application of UV-spectrophotometric methods for estimation of tenofovir disoproxil fumarate in tablets,” Pakistan Journal of Pharmaceutical Sciences, vol. 22, no. 1, pp. 27–29, 2009.
[14]  V. P. Choudari, S. Ingale, S. R. Gite, D. D. Tajane, V. G. Modak, and A. Ambekar, “Spectrophotometric simultaneous determination of Tenofovir disoproxil fumarate and emtricitabine in combined form by ratio derivative, first order derivative and absorbance corrected method and its application to dissolution study,” Pharmaceutical Methods, vol. 2, pp. 47–52, 2011.
[15]  J. O. Onah and U. Ajima, “Spectrophotometric determination of tenofovir disoproxil fumarate after complexation with ammonium molybdate and picric acid,” International Journal of Drug Development and Research, vol. 3, no. 1, pp. 199–204, 2011.
[16]  H. T. S. Britton, Hydrogen Ions, vol. 1, Chapman and Hall, London, UK, 1942.
[17]  W. C. Vosburgh and G. R. Coopper, “The identification of complex ions in solution spectrometric measurements,” Journal of the American Chemical Society, vol. 63, no. 437, 1941.
[18]  W. Likussar and D. F. Boltz, “Theory of continuous variations plots and a new method for spectrophotometric determination of extraction and formation constants,” Analytical Chemistry, vol. 43, no. 10, pp. 1265–1272, 1971.
[19]  K. Momoki, J. Sekino, H. Sato, and N. Yamaguchi, “Theory of curved molar ratio plots and a new linear plotting method,” Analytical Chemistry, vol. 41, no. 10, pp. 1286–1299, 1969.
[20]  “International Conference on Harmonization (ICH) of Technical Requirement for the Registration of Pharmaceuticals for Human use, Validation of Analytical procedures definitions and Terminology Genera,” 1996.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133